Immunotherapy and chemotherapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (ivonescimab) plus chemotherapy given before surgery for esophageal cancer. The goal is to see if it can shrink the tumor and improve outcomes compared to surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your esophageal cancer must be a type called squamous cell carcinoma and be at stage II or III (spread to nearby lymph nodes but not far).
- You must be able to have surgery to remove the cancer.
- You should be in good enough health to carry out daily activities (ECOG score 0 or 1).
- Your blood counts, kidney, liver, and heart function must be within acceptable ranges.
- You cannot have had any prior cancer treatment (like chemotherapy, radiation, or surgery) for this cancer.
- You cannot have an active autoimmune disease or a history of one (like lupus, rheumatoid arthritis, or inflammatory bowel disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer) and palbociclib (a targeted therapy that stops cancer cells from growing)—given before surgery for esophageal cancer. The goal is to see if this combination shrinks the tumor and improves treatment outcomes.
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can shrink esophageal cancer and improve outcomes. It is designed for patients with early-stage but treatable esophageal squamous cell carcinoma who are candidates for surgery.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
Hear when a new Esophageal Squamour Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.